Controlled trial of amitriptyline in general practice.
A controlled double-blind trial of amitriptyline at two dosage levels (75 and 150 mg/day), amylobarbitone (150 mg/day), and an inert substance for a period of four weeks was conducted on four matched groups of women attending their general practitioners and suffering from a depressive illness. Improvement at 7 and 28 days was noted on several measures of depression and anxiety in all treatment groups. Of these treatments amitriptyline 150 mg/day was the most consistent in relieving depression and anxiety. Troublesome side effects were equally distributed among the four treatments.
D000293:Adolescent; D000328:Adult; D000639:Amitriptyline / Q000008:administration & dosage* / Q000009:adverse effects; D000654:Amobarbital / Q000009:adverse effects / Q000627:therapeutic use; D001007:Anxiety / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy*; D005194:Family Practice; D005260:Female; D006801:Humans; D010919:Placebos
D010919:Placebos; D000639:Amitriptyline; D000654:Amobarbital